EP2004173A2 - Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies - Google Patents
Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathiesInfo
- Publication number
- EP2004173A2 EP2004173A2 EP07734240A EP07734240A EP2004173A2 EP 2004173 A2 EP2004173 A2 EP 2004173A2 EP 07734240 A EP07734240 A EP 07734240A EP 07734240 A EP07734240 A EP 07734240A EP 2004173 A2 EP2004173 A2 EP 2004173A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- medicament
- use according
- aminapthone
- aminaphtone
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- YLMPBJUYFTWHKJ-UHFFFAOYSA-N aminaphthone Chemical compound CC1=C(O)C2=CC=CC=C2C(O)=C1OC(=O)C1=CC=C(N)C=C1 YLMPBJUYFTWHKJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 230000003412 degenerative effect Effects 0.000 claims abstract description 6
- 230000003511 endothelial effect Effects 0.000 claims description 12
- 200000000007 Arterial disease Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000003782 Raynaud disease Diseases 0.000 claims description 4
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical group Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 claims description 3
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 29
- 102100033902 Endothelin-1 Human genes 0.000 description 17
- 101800004490 Endothelin-1 Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000007640 basal medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 5
- 108050009340 Endothelin Proteins 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000011891 EIA kit Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000015689 E-Selectin Human genes 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000404883 Pisa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- -1 parabens Chemical compound 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the subject of the present invention is a novel use of the compound 2-hydroxy-3 -methyl-1, 4-napthohydroquino- ne-2-p-aminobenzoate, known by the common name a ' tni- naphtone (hereinafter defined, by simplicity, as aminapthone) , for the preparation of a medicament for treating arteriophaties; in particular, for the treatment, at the endothelial level, of arteriopathies of a degenerative inflammatory type.
- a tni- naphtone hereinafter defined, by simplicity, as aminapthone
- Aminaphtone is a compound having a known pharmacological activity and commercially available in Italy and other countries for many years; in Italy, for example, it constitutes the active substance of the CAPILLAREMA drug, a medicine of Laboratori Baldacci S.p.A., Pisa.
- the drug is widely used 'in the symptomatic treatment of chronic venous failure of the lower limbs, a situation in which the hematic stasis affects the microcirculation by producing alterations of the structure arid the capillary functionality.
- Pharmacological and clinical properties of this product have been published on scientific reviews and confirmed in these last years by the therapeutic use for the treatment of venous pathologies in countries where it is commercialized.
- aminaphtone also has the ability of antagonizing pathological events referable to an • inflammatory state of the arterial vasal structure through different mechanisms than those currently known has never been shown.
- the vascular • endothelium results to be a system, consisting of me- tabolically active cells and responsive to physiological stimuli. Said stimuli control in a meticulous way the blood flow, acting a complex role in the control of vasoreactivity> platelet aggregation and the resistance to thrombi formation.
- endothelial cells synthesize and secrete components of the connective tissue and molecules with an antagonist ac- tivity therebetween.
- the endothelial inflammation is at the basis of degenerative/inflammatory pathologies, with an evolutionary character, with the presence of vacuolization, loss of endothelial integrity, perivascular infiltration of lymphdcy-t ' SsV ' ⁇ macrophages, ' monocytes, fibroblasts, and increasing expression of adhesive molecules with the formation of a strong endogenous vasoconstrictor, such as endothelin, with a following hyperplasia of the in- tima, proliferation of smooth muscle cells of the vessels and a vascular remodelling.
- a strong endogenous vasoconstrictor such as endothelin
- statins drugs, which have however a double disadvantage: they are expensive therapies and determine, in an absolutely not negligible part of patients, a form of statin myopathy.
- the object 'of the present invention is to provide an answer to the need above pointed out .
- An object of the present invention is the use of aminapthone for the preparation of a drug for treating artheriopathies, as reported in the appended independent claim.
- Figure 1 it graphically reports the inhibitory effect exerted by aminapthone, at different dosages, on the expression of the adhesive molecule E-selectine (ELAM- 1) from human endothelial cells ECV 304. Specifically, Fig.
- FIG. 1 shows the density of membrane ELAM-I fluorescence, determined through cytofluorometric analysis (mean channel) in different samples of ECV 304 cells, in the following conditions, respectively: a.) in basal (Medium) and after a 48 hr incubation with basal medium additioned with aminapthone at a dosage of 4 mcg/ml (Amna) ; b.) after incubation/activation for 48 hr with IL-l ⁇ at 100 U/ml (IL-I) and, respectively, IL-I additioned with aminapthone (Amna) at concentrions of 2; 4; 5 mcg/ml . - .
- Figure 2 it reports, in a block diagram, the inhibitory effect exerted by aminaphtone, at different dosages, on the endothelin production (ET-I) from human' endothelial cells ECV 304 incubated/activated with IL- l ⁇ .
- Fig. 2 shows the, course of the ET-I production, dosed with a specific EIA-Kit, in different samples of ECV 304 activated with IL-l ⁇ alone at 100 U/ml (IL-I) and, respectively, with IL-I addi- tioned with aminapthone at concentrations of 2, 4, 6 racg/ml (A2 ; A4 ; A6) .
- Figure 3 it reports, in a block diagram, the inhibitory effect exerted by aminaphtone, at different dosages, on the endothelin production (ET-I) from non- activated human endothelial cells ECV 304.
- Fig. 3 shows the course of the ET-I production in different samples of ECV 304 non-activated with IL- l ⁇ but incubated with the culture medium (basal) alone and, respectively, with basal medium additioned with aminapthone at concentrations of 2 ; 4 ; 6 mcg/ml (A2 ; A4; A6) .
- the present invention relates to the use of aminapthone for the preparation of a medicament .
- aminapthone for the treatment of arteriophaties; preferably, • of all those types of arteriophaties referable to an inflammatory state of the arterial vasal structure; more preferably, of the endothelium.
- said medicament could result suitable for the therapeutic treatment of: arteriosclerosis, atherosclerosis, obliterative arteriopathy, Raynaud disease secondary to connectivitis, primitive and secondary pulmonary hypertension, diabetic microangiopathy, Buerger's disease, systemic sclerosis and in all diseases characterized by endothelial damage and activation and consequent tissue ischemia.
- the preparation of the medicament of the present invention is carried out in ' a traditional way by using, depending on the type of formulation that one wishes to prepare, " preparative techniques known to the skilled in the pharmaceutical sector.
- Said preparation includes at least a step in which a therapeutically effective dose of active substance aminapthone, subject of the present invention, is additioned with a quantity of proper additives and excipients selected from: carriers, buffering agents, lubricants, dispers- ants, flavourings, sweeteners, stabilizers, preservatives, antioxidants commonly used in the pharmaceutical formulation technique.
- starch starch
- tween flavours, such as those of mandarin, grapefruit, strawberry, bilberry, all fruits, sucrose, glucose, acesulfame, saccharin, aspartame, ascorbic acid, parabens, glutamine, arginine, superoxide dismutase, glutathione.
- Said medicament can be administered to patients by different administration routes.
- a particularly preferred medicament of the present invention is formu- lated for oral administration.
- compositions for oral administration are, for example, in form of capsules, beads, solutions or suspensions ready to drink, powders or granulates in sachets (to be suspended or dissolved in water or non- carbonated and non-alcoholic beverages at the time of use) or similar forms, tablets, effervescent formulations .
- the medicament of the present invention can also be formulated in a coated, lacquered, encapsulated or microencapsulated form, so as to result gastroresis- tant.
- Said medicament can also be formulated as a con- trolled-release form, so as to selectively release the active substances in the intestinal tract, particularly the colon.
- parenteral or transdermic administration can be foreseen.
- said medicament contains the active substance aminaphtone in a quantity between 30 and 150 mg/dose; preferably, from 50 to 100 mg/dose.
- Said medicament is usually administered to the patient at a dosage between, on average, 75 and 450 mg/die; preferably, from 50 to 300 mg/die; more preferably, from 75 to 225 mg/die.
- the medicament of the present invention including aminaphtone, has pointed out a direct protective effect of the arterial vascular endothelium through the block of cell and transcriptional mechanisms which are involved in the endothelial damage.
- IL-i ⁇ represents a molecule also produced by humans in inflammation conditions and it is responsible for that series of alterations falling within the context of acute stage answers to stimuli .
- ECV 304 cells are a human cell line presenting many- features of endothelial cells and is commonly used for studying, in a standardized way, cell functions thereof .
- E-selectine expression covers an important role in arterial vascular pathologies by promoting the adhesion of platelets and the adhesion and the migration of inflammatory cells.
- endothelin-1 production has been analyzed as it is fundamental in vasoconstriction and vascular remodelling processes typical of the endothelial injury.
- Endothelin-1 is in fact mentioned as one of the determining pathogenic principles of several human pathologies, for example: primitive and secondary pulmonary hypertension, secondary Raynaud disease, inflammatory arteriopathies and atherosclerosis; it further promotes the hypertro- phic cardiomiopathy and the increase of the arterial pressure.
- Cell lines ECV 304 they are cells coming from umbilical cord of a female Japanese new-born and spontane- ously immortalized at the 136 th step (distributed from Collection of Cell Cultures) . Such cells were cultured in a complete medium consisted of: Medium 199, L- glutamine 1%, penicillin/streptomycin 1% (Invitrogen) with an addition of 10% FCS (fetal calf serum) (Hy- clone) .
- FCS fetal calf serum
- Cells of the ECV304 line cultured in 28 cm 2 Petri dishes, were stimulated with IL-l ⁇ at 100 U/ml (Roche) over 48 hrs in a complete medium and complete medium additioned with aminaphtone at the concentration of 2; 4; 5 ⁇ g/ml, ' respectively.
- concentrations are equivalent to concentrations reached "in vivo" through administration of Capillarema per os at the standard dosage of 3 capsules/day (capsules with 75 mg of active substance per day) .
- cells untreated with IL-l ⁇ were incubated in a complete medium additioned with aminaphtone alone at the concentration of 4 ⁇ g/ml .
- EIA-kit - Supernatants of cell samples ECV304 were collected, cultured as above, treated with IL-l ⁇ at 100 U/ml over 6-12-24 and 36 hrs or with IL-l ⁇ at 100 U/ml additioned with aminaphtone at the concentration of 2; 4; 6 ⁇ g/ml , respectively.
- samples non- stimulated with IL-l ⁇ were incubated with the addition of aminaphtone alone at 2 ; 4 ; 6 ⁇ g/ml .
- the concentration of ET-I existing in the supernatants was quantified through Endothelin-1 EIA-Kit (CAYMAN Chemical) in an interval between 0 and 250 pg/ml .
- This immunometric test is based on the "sandwich” technique with a double antibody.
- PPET- 1 Real-Time RT-PCR specific for Pre-Pro-ET-1 (PPET- 1) .
- PPET-I gene was detected at 6- 12-24-36 hrs, respectively, in samples: treated with IL-l ⁇ (100 U/ml) ; treated with IL-l ⁇ (100 U/ml) additioned with aminaphtone (2; 4; 6 ⁇ h/ml) ; non-stimulated by IL-l ⁇ but treated with aminaphtone alone.
- RT-PCR technique 'based on TaqMan technology was used (Applied Biosystems, Foster City, CA) , through a sequence determination system ABI PRISM 7000 (Applied Biosystems) . 2-4 ⁇ l were collected form each cDNA, diluted 1:5, in a final volume of 25 ⁇ l .
- PCR mix containing ' Ix TaqMan Universal PCR Master Mix with Ampo- Erase UNG enzyme; a specific primer and a probe FAM- labelled mix (Assay-On-Demand Gene Expression Products; Applied Biosystems) .
- AmpliTaq Gold enzyme was activated over 10 min. at 95 0 C. All genes were then amplified: a first step of 15 sec. At 95°C; a second step of 1 min. at 60 0 C; all for 50 total cycles.
- the quantification of the specific mRNA PPET-I was normalized for the constitutive gene expression glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) .
- GPDH glyceraldehyde-3-phosphate-dehydrogenase
- CT comparative method CT
- the CT value was defined as the number of PCR cycles required for overcome the fluorescence signal (defined as 10-fold the standard deviation of the basal variation) .
- the ⁇ CT value was defined as the difference between CT of mRNA PPET-I and CT of mRNA GAPDH. The course of the mRNA PPET expression was computed according to the formula 2-
- ⁇ CT results to be the difference between each ⁇ CT and the ⁇ CT of the sample having the lowest mRNA (calibrator) .
- aminapthone is capable of reducing in a statistically significant way the E-selectine expression (ELAM-I) in ECV304 cells (MC: mean ⁇ standard deviation: 219 ⁇ 8.3; % positive cells 19.4 ⁇ 1.7) relative to cells incubated with the complete culture medium alone (MC: mean ⁇ standard deviation: 250 + 22 p ⁇ 0.05; % positive cells 29.1 ⁇ 3.1; p ⁇ 0.05).
- aminapthone inhibits " , with a dose-dependent course, the expression of adhesive molecules in activated cells; (cells incubated with IL-l ⁇ 100 U/ml : MC: mean + standard deviation: 369.6 ⁇ 30.5; % positive cells: 38.4 ' + 3.7); (cells incubated with IL-l ⁇ 100 U/ml.
- EIA-kit confirms the trend, already observed at a level of gene transcription of PRE-PRO-ET-I, according to which aminapthone tends to reduce the ET-I production from samples of ECV304 cells, both stimulated with IL-I and incubated with the culture medium alone. Furthermore, it has been noted that such inhibition on ET-I production resulted confirmed in all times and had a dose-dependent course. (Fig. 2 and 3) . The trend to a linear decrement of the ET-I concentration in different times with increasing concentrations of aminapthone has reached a statistical significance in the following cases :
- basal medium vs . aminapthone 4 mcg/ml p ⁇ 0.05
- basal medium vs. aminapthone 6 mcg/ml p ⁇ 0.05
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11153882.3A EP2335695B1 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000712A ITMI20060712A1 (it) | 2006-04-11 | 2006-04-11 | Uso di aminaftone per la preparazione di un medicamento per il trattamento delle arteriopatie |
PCT/IB2007/000921 WO2007116297A2 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11153882.3A Division EP2335695B1 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
EP11153882.3 Division-Into | 2011-02-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2004173A2 true EP2004173A2 (fr) | 2008-12-24 |
EP2004173B1 EP2004173B1 (fr) | 2011-10-12 |
Family
ID=38480588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07734240A Active EP2004173B1 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
EP11153882.3A Active EP2335695B1 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11153882.3A Active EP2335695B1 (fr) | 2006-04-11 | 2007-04-10 | Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies |
Country Status (10)
Country | Link |
---|---|
US (2) | US8202903B2 (fr) |
EP (2) | EP2004173B1 (fr) |
JP (1) | JP2009533414A (fr) |
AT (1) | ATE527997T1 (fr) |
BR (1) | BRPI0711841A2 (fr) |
CA (1) | CA2648751C (fr) |
ES (2) | ES2519345T3 (fr) |
IT (1) | ITMI20060712A1 (fr) |
PT (2) | PT2335695E (fr) |
WO (1) | WO2007116297A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1400389B1 (it) * | 2010-05-27 | 2013-05-31 | Baldacci Lab Spa | Aminaftone per uso nel trattamento e/o nella prevenzione dell'emicrania |
US9753909B2 (en) | 2012-09-07 | 2017-09-05 | Splunk, Inc. | Advanced field extractor with multiple positive examples |
US9152929B2 (en) | 2013-01-23 | 2015-10-06 | Splunk Inc. | Real time display of statistics and values for selected regular expressions |
IT201900006572A1 (it) * | 2019-05-06 | 2020-11-06 | Laboratori Baldacci Spa | Nuovo metodo di analisi hplc dell'aminaftone |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT252224B (de) * | 1964-10-05 | 1967-02-10 | Finanz Kompensations Anst | Verfahren zur Herstellung von neuen 2-Aminobenzoyloxy-naphthohydrochinonen |
ES456574A1 (es) * | 1977-03-07 | 1978-02-16 | Rocador Sa | Procedimiento de obtencion de pentametil-carbamato de quer- cetina. |
IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
US5648377A (en) * | 1993-12-21 | 1997-07-15 | Indena S.P.A. | Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals |
IT1275955B1 (it) * | 1995-03-22 | 1997-10-24 | Dompe Spa | Formulazioni farmaceutiche in forma di gel tissotropico |
DK1317272T3 (da) * | 2000-05-25 | 2006-08-14 | Boehringer Ingelheim Int | Middel til forbedret cellebeskyttelse omfattende en lipofil antioxidant og en hydrofil antioxidant |
JP2003238439A (ja) * | 2002-02-13 | 2003-08-27 | Yasuhiko Tabata | 虚血治療剤 |
JPWO2003094917A1 (ja) * | 2002-05-13 | 2005-09-08 | 高田製薬株式会社 | ビントペロール含有経皮投与用医薬組成物 |
US7202222B2 (en) * | 2003-01-06 | 2007-04-10 | National Bioscience Corporation | Methods for treatment of obesity and effective fat loss promotion |
JP4598593B2 (ja) * | 2004-05-10 | 2010-12-15 | 晶岩 韓 | 虚血再灌流による微小循環障害の予防・治療用薬剤 |
-
2006
- 2006-04-11 IT IT000712A patent/ITMI20060712A1/it unknown
-
2007
- 2007-04-10 US US12/296,872 patent/US8202903B2/en active Active
- 2007-04-10 JP JP2009504844A patent/JP2009533414A/ja active Pending
- 2007-04-10 ES ES11153882.3T patent/ES2519345T3/es active Active
- 2007-04-10 AT AT07734240T patent/ATE527997T1/de active
- 2007-04-10 EP EP07734240A patent/EP2004173B1/fr active Active
- 2007-04-10 WO PCT/IB2007/000921 patent/WO2007116297A2/fr active Application Filing
- 2007-04-10 BR BRPI0711841-4A patent/BRPI0711841A2/pt active IP Right Grant
- 2007-04-10 PT PT111538823T patent/PT2335695E/pt unknown
- 2007-04-10 EP EP11153882.3A patent/EP2335695B1/fr active Active
- 2007-04-10 ES ES07734240T patent/ES2374659T3/es active Active
- 2007-04-10 PT PT07734240T patent/PT2004173E/pt unknown
- 2007-04-10 CA CA2648751A patent/CA2648751C/fr active Active
-
2011
- 2011-01-13 US US13/005,902 patent/US10028929B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2007116297A2 * |
Also Published As
Publication number | Publication date |
---|---|
PT2335695E (pt) | 2014-10-29 |
WO2007116297A3 (fr) | 2008-01-10 |
CA2648751C (fr) | 2013-01-22 |
EP2335695A1 (fr) | 2011-06-22 |
CA2648751A1 (fr) | 2007-10-18 |
PT2004173E (pt) | 2012-01-11 |
US8202903B2 (en) | 2012-06-19 |
US20120022155A1 (en) | 2012-01-26 |
US20090182045A1 (en) | 2009-07-16 |
ES2374659T3 (es) | 2012-02-20 |
JP2009533414A (ja) | 2009-09-17 |
EP2335695B1 (fr) | 2014-08-20 |
EP2004173B1 (fr) | 2011-10-12 |
WO2007116297A2 (fr) | 2007-10-18 |
US10028929B2 (en) | 2018-07-24 |
ATE527997T1 (de) | 2011-10-15 |
BRPI0711841A2 (pt) | 2011-12-13 |
ITMI20060712A1 (it) | 2007-10-12 |
ES2519345T3 (es) | 2014-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ke et al. | A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro-and anti-inflammatory cytokines in patients undergoing open cholecystectomy | |
US8343947B2 (en) | Therapeutic treatment | |
US5958978A (en) | Specific cyclooxygenase 2 inhibitor and anti-inflammatory agent | |
US10028929B2 (en) | Method of treating raynaud's disease secondary to connectivitis using aminaphtone | |
JP2020524689A (ja) | Pai−1過剰発現に関連する状態のプラスミノーゲン処置 | |
Cudmore et al. | Effects of oral clenbuterol on the clinical and inflammatory response to endotoxaemia in the horse | |
US20060160896A1 (en) | Therapeutic treatment | |
BR112016005601B1 (pt) | composto, composição farmacêutica, e usos de um composto | |
ZA200201619B (en) | Use of amino acids for making medicines for treating to insulin-resistance. | |
CN113304133A (zh) | 贝壳杉烷类化合物在制备预防和治疗炎症性肠病的药物中的应用 | |
JPH06234636A (ja) | インターロイキン8を阻害するためのレフルノミドの使用 | |
Kurata et al. | Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia | |
RU2496493C1 (ru) | Способ профилактики острого послеоперационного панкреатита | |
US8518995B2 (en) | Methods and compositions for the treatment of irritable bowel syndrome | |
Hu et al. | Mangiferin alleviates renal inflammatory injury in spontaneously hypertensive rats by inhibiting MCP-1/CCR2 signaling pathway | |
TWI489982B (zh) | 苯醌類化合物應用於抑制動脈粥狀血管硬化之用途 | |
SU1311710A1 (ru) | Способ лечени острого послеоперационного панкреатита | |
Rieder et al. | Passage of sulfamethoxazole and trimethoprim into the bile in man | |
Dinar | A review on the emerging role of SIRT6 in cardiovascular diseases | |
Leithäuser et al. | The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis? | |
CN115666560A (zh) | 用于治疗covid-19的血栓素a2受体拮抗剂的方法和药物组合物 | |
RU2523450C1 (ru) | Способ профликатики ранней послеоперационной когнитивной дисфункции у пациентов после коронарного шунтирования в условиях искуственного кровообращения | |
CN117752649A (zh) | 桑根酮c在制备抗血小板聚集、抗血栓形成药物中的应用 | |
Rubegni et al. | Effects of intravenous indoprofen on bleeding time and other haemostatic parameters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081016 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090211 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FONDAZIONE IRCCS ''CA' GRANDA - OSPEDALE MAGGIORE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007017785 Country of ref document: DE Effective date: 20111215 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BUGNION S.A. |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20111228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2374659 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120220 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20111012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120112 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
26N | No opposition filed |
Effective date: 20120713 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007017785 Country of ref document: DE Effective date: 20120713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120430 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: LABORATORI BALDACCI S.P.A., IT Effective date: 20130910 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: LABORATORI BALDACCI S.P.A., IT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070410 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602007017785 Country of ref document: DE Representative=s name: BETTEN & RESCH PATENT- UND RECHTSANWAELTE PART, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602007017785 Country of ref document: DE Owner name: LABORATORI BALDACCI S.P.A., IT Free format text: FORMER OWNER: FONDAZIONE IRCCS "CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO", MAILAND, IT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20160421 AND 20160428 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL AND PARTN, CH Ref country code: CH Ref legal event code: PUE Owner name: LABORATORI BALDACCI S.P.A., IT Free format text: FORMER OWNER: FONDAZIONE IRCCS ''CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO'', IT |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: LABORATORI BALDACCI S.P.A.; IT Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: FONDAZIONE IRCCS ''CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO'' Effective date: 20160926 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: LABORATORI BALDACCI S.P.A Effective date: 20161028 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 527997 Country of ref document: AT Kind code of ref document: T Owner name: LABORATORI BALDACCI S.P.A., IT Effective date: 20180730 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230517 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20240327 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240426 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240429 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240429 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240503 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20240320 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240418 Year of fee payment: 18 Ref country code: FR Payment date: 20240425 Year of fee payment: 18 |